- Home
- ESGL vs ENTX Comparison
ESGL vs ENTX Comparison
Compare ESGL & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ESGL | ENTX |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.3M | 142.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ESGL | ENTX |
|---|---|---|
| Price | $4.00 | $2.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 6.4K | ★ 81.7K |
| Earning Date | 12-26-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,328,277.00 | $124,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 25.25 |
| 52 Week Low | $0.90 | $1.50 |
| 52 Week High | $4.32 | $3.22 |
Technical Indicators
Market Signals| Indicator | ESGL | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.13 | 36.71 |
| Support Level | $3.75 | $2.05 |
| Resistance Level | $3.95 | $2.53 |
| Average True Range (ATR) | 0.17 | 0.22 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 100.00 | 13.42 |
Price Performance
Historical ComparisonAbout ESGL ESGL Holdings Limited
ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.